{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:50Z","timestamp":1792783130488,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T00:00:00Z","timestamp":1783728000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Basel","id":[{"id":"https:\/\/ror.org\/02s6k3f65","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Health Care and Philos"],"published-print":{"date-parts":[[2026,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Precision medicine (PM) promises better outcomes by aligning prevention and treatment with molecular and phenotypic profiles. But precision is not merely a clinical refinement; it is an epistemic shift in how health systems classify risk, allocate eligibility and define value. In this study, we argue that broad adoption of PM creates structural tension within solidarity-based health systems and exposes limits in conventional cost-effectiveness evaluation. Ethically, PM converts pooled probabilistic uncertainty into individualized biological prediction, making access increasingly conditional on measurement, interpretation and pathway completion. Economically, PM fragments evaluable populations, destabilizes counterfactual comparison and shifts value from discrete products to information-dependent care pathways. As a result, standard metrics such as the incremental cost-effectiveness ratio (ICER) often become sensitive not only to biological effect, but also to governance: who is tested, how results are interpreted, which downstream services are funded and who can complete the pathway. We suggest that the instability observed in PM appraisal is not simply a technical problem of modeling, but a sign that the object of evaluation has changed. Recognizing this structural shift is essential if PM is to be integrated into health systems committed to both equity and evaluability.<\/jats:p>","DOI":"10.1007\/s11019-026-10381-z","type":"journal-article","created":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T07:36:52Z","timestamp":1783755412000},"page":"923-930","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The dis-economy of precision medicine: how stratification multiplies social tension in healthcare systems"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-5266-6178","authenticated-orcid":false,"given":"Raef","family":"Kozman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3903-6874","authenticated-orcid":false,"given":"Fabrice","family":"Jotterand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,11]]},"reference":[{"key":"10381_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s12914-015-0056-9","volume":"15","author":"GA Abiiro","year":"2015","unstructured":"Abiiro, G.A., and M. De Allegri. 2015. Universal health coverage from multiple perspectives: A synthesis of conceptual literature and global debates. BMC International Health and Human Rights 15: 17. https:\/\/doi.org\/10.1186\/s12914-015-0056-9.","journal-title":"BMC International Health and Human Rights"},{"issue":"1","key":"10381_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.cell.2019.02.039","volume":"177","author":"NS Abul-Husn","year":"2019","unstructured":"Abul-Husn, N.S., and E.E. Kenny. 2019. Personalized medicine and the power of electronic health records. Cell 177 (1): 58\u201369. https:\/\/doi.org\/10.1016\/j.cell.2019.02.039.","journal-title":"Cell"},{"key":"10381_CR3","unstructured":"Alliance, G. 2009. ScreeningServices TNYMAC for G and N. GENETIC TESTING. In: Understanding Genetics: A New York, Mid-Atlantic Guide for Patients and Health Professionals. Genetic Alliance; Accessed March 25, 2026. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK115571\/"},{"issue":"Suppl 1","key":"10381_CR4","doi-asserted-by":"publisher","first-page":"e010724","DOI":"10.1136\/bmjgh-2022-010724","volume":"8","author":"A Alwan","year":"2023","unstructured":"Alwan, A., G. Yamey, and A. Soucat. 2023. Essential packages of health services in low-income and lower-middle-income countries: what have we learnt? BMJ Glob Health 8(Suppl 1):e010724. https:\/\/doi.org\/10.1136\/bmjgh-2022-010724","journal-title":"BMJ Glob Health"},{"key":"10381_CR5","doi-asserted-by":"publisher","DOI":"10.1596\/978-0-8213-6571-7","volume-title":"Beyond Survival: Protecting Households from Health Shocks in Latin America","author":"CC Baeza","year":"2006","unstructured":"Baeza, C.C., and T.G. Packard. 2006. Beyond Survival: Protecting Households from Health Shocks in Latin America. The World Bank. https:\/\/doi.org\/10.1596\/978-0-8213-6571-7."},{"issue":"1","key":"10381_CR6","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s13073-016-0388-7","volume":"8","author":"JS Beckmann","year":"2016","unstructured":"Beckmann, J.S., and D. Lew. 2016. Reconciling evidence-based medicine and precision medicine in the era of big data: Challenges and opportunities. Genome Medicine 8: 134. https:\/\/doi.org\/10.1186\/s13073-016-0388-7.","journal-title":"Genome Medicine"},{"issue":"7210","key":"10381_CR7","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/bmj.319.7210.635","volume":"319","author":"AH Briggs","year":"1999","unstructured":"Briggs, A. H., and A. M. Gray. 1999. Handling uncertainty in economic evaluations of healthcare interventions. Bmj 319(7210):635\u2013638. https:\/\/doi.org\/10.1136\/bmj.319.7210.635","journal-title":"Bmj"},{"issue":"1","key":"10381_CR8","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2217\/pme.14.65","volume":"12","author":"KB Brothers","year":"2015","unstructured":"Brothers, K. B., and M. A. Rothstein. 2015. Ethical, legal and social implications of incorporating personalized medicine into healthcare. Per Med 12(1):43\u201351. https:\/\/doi.org\/10.2217\/pme.14.65","journal-title":"Per Med"},{"issue":"9","key":"10381_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.jval.2023.05.001","volume":"26","author":"W Chen","year":"2023","unstructured":"Chen, W., Y. Wang, and Y. Zemlyanska et al. 2023. Evaluating the Value for Money of Precision Medicine from Early Cycle to Market Access: A Comprehensive Review of Approaches and Challenges. Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research 26(9):1425\u20131434. https:\/\/doi.org\/10.1016\/j.jval.2023.05.001","journal-title":"Value In Health : The Journal Of The International Society For Pharmacoeconomics And Outcomes Research"},{"issue":"2","key":"10381_CR10","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1111\/1468-0009.12453","volume":"98","author":"T Cheng","year":"2020","unstructured":"Cheng, T. 2020. Bending the cost growth curve and expanding coverage: Lessons from Germany\u2019s all-payer system a tribute to Uwe Reinhardt. Milbank Quarterly 98 (2): 279\u2013296. https:\/\/doi.org\/10.1111\/1468-0009.12453.","journal-title":"Milbank Quarterly"},{"issue":"1","key":"10381_CR11","doi-asserted-by":"publisher","first-page":"21","DOI":"10.3892\/mco.2021.2453","volume":"16","author":"K Christofyllakis","year":"2022","unstructured":"Christofyllakis, K., J. T. Bittenbring, and L. Thurner et al. 2022. Cost-effectiveness of precision cancer medicine-current challenges in the use of next generation sequencing for comprehensive tumour genomic profiling and the role of clinical utility frameworks (Review). Mol Clin Oncol 16(1):21. https:\/\/doi.org\/10.3892\/mco.2021.2453","journal-title":"Mol Clin Oncol"},{"issue":"7","key":"10381_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41562-021-01121-9","volume":"5","author":"L Cronk","year":"2021","unstructured":"Cronk, L., and A. Aktipis. 2021. Design principles for risk-pooling systems. Nat Hum Behav 5(7):825\u2013833. https:\/\/doi.org\/10.1038\/s41562-021-01121-9","journal-title":"Nat Hum Behav"},{"key":"10381_CR13","unstructured":"Economic Evaluation | NICE technology appraisal and highly specialised technologies guidance: the manual | Guidance | NICE. January 31, 2022. Accessed March 25, 2026. https:\/\/www.nice.org.uk\/process\/pmg36\/chapter\/economic-evaluation-2"},{"key":"10381_CR14","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1017\/pcm.2023.3","volume":"1","author":"A Edsj\u00f6","year":"2023","unstructured":"Edsj\u00f6, A., A. Lindstrand, and D. Gisselsson et al. 2023. Building a precision medicine infrastructure at a national level: The Swedish experience. Camb Prism Precis Med 1:e15. https:\/\/doi.org\/10.1017\/pcm.2023.3","journal-title":"Camb Prism Precis Med"},{"issue":"5","key":"10381_CR15","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jval.2019.11.010","volume":"23","author":"E Faulkner","year":"2020","unstructured":"Faulkner, E., A. P. Holtorf, and S. Walton et al. 2020. Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. Value in Health 23(5):529\u2013539. https:\/\/doi.org\/10.1016\/j.jval.2019.11.010","journal-title":"Value in Health"},{"issue":"2","key":"10381_CR16","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s11019-022-10067-2","volume":"25","author":"LM Fleck","year":"2022","unstructured":"Fleck, L. M. 2022. Precision medicine and the fragmentation of solidarity (and justice). Medicine, Health Care And Philosophy 25(2):191\u2013206. https:\/\/doi.org\/10.1007\/s11019-022-10067-2","journal-title":"Medicine, Health Care And Philosophy"},{"issue":"1","key":"10381_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/23808993.2018.1421858","volume":"3","author":"SP Gavan","year":"2018","unstructured":"Gavan, S.P., A.J. Thompson, and K. Payne. 2018. The economic case for precision medicine. Expert Review of Precision Medicine and Drug Development 3 (1): 1\u20139. https:\/\/doi.org\/10.1080\/23808993.2018.1421858.","journal-title":"Expert Review of Precision Medicine and Drug Development"},{"issue":"3","key":"10381_CR18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11019-023-10158-8","volume":"26","author":"S Green","year":"2023","unstructured":"Green, S., B. Prainsack, and M. Sabatello. 2023. Precision medicine and the problem of structural injustice. Medicine, Health Care And Philosophy 26(3):433\u2013450. https:\/\/doi.org\/10.1007\/s11019-023-10158-8","journal-title":"Medicine, Health Care And Philosophy"},{"issue":"1","key":"10381_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2217\/pme-2023-0097","volume":"21","author":"S Green","year":"2023","unstructured":"Green, S., B. Prainsack, and M. Sabatello. 2023. The roots of (in)equity in precision medicine: Gaps in the discourse. Personalized Medicine 21 (1): 5\u20139. https:\/\/doi.org\/10.2217\/pme-2023-0097.","journal-title":"Personalized Medicine"},{"issue":"2","key":"10381_CR20","first-page":"29","volume":"3","author":"S Gre\u00df","year":"2007","unstructured":"Gre\u00df, S. 2007. Private Health Insurance in Germany: Consequences of a Dual System. Healthc Policy 3(2):29\u201337.","journal-title":"Healthc Policy"},{"issue":"1","key":"10381_CR21","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1086\/302714","volume":"66","author":"MA Hall","year":"2000","unstructured":"Hall, M. A., and S. S. Rich. 2000. Laws Restricting Health Insurers\u2019 Use of Genetic Information: Impact on Genetic Discrimination. American Journal Of Human Genetics 66(1):293\u2013307. https:\/\/doi.org\/10.1086\/302714","journal-title":"American Journal Of Human Genetics"},{"key":"10381_CR22","doi-asserted-by":"publisher","first-page":"100027","DOI":"10.1016\/j.premed.2025.100027","volume":"5","author":"S Hersey","year":"2026","unstructured":"Hersey, S., C. Scott, S. Rosen, P. Kavita, Keeling, and M. Lawler. 2026. Precision medicine: What is so difficult? The interplay and complexities of pharmaceutical and diagnostic partnerships to deliver the promise of precision medicine. The Journal of Precision Medicine: Health and Disease 5:100027. https:\/\/doi.org\/10.1016\/j.premed.2025.100027","journal-title":"The Journal of Precision Medicine: Health and Disease"},{"issue":"23","key":"10381_CR23","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1056\/NEJMsb1503104","volume":"372","author":"JL Jameson","year":"2015","unstructured":"Jameson, J. L., and D. L. Longo. 2015. Precision Medicine \u2014 Personalized, Problematic, and Promising. New England Journal of Medicine 372(23):2229\u20132234. https:\/\/doi.org\/10.1056\/NEJMsb1503104","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10381_CR24","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00038-019-01298-x","volume":"64","author":"M Kasztura","year":"2019","unstructured":"Kasztura, M., A. Richard, N. E. Bempong, D. Loncar, and A. Flahault. 2019. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health 64(9):1261\u20131271. https:\/\/doi.org\/10.1007\/s00038-019-01298-x","journal-title":"Int J Public Health"},{"issue":"1","key":"10381_CR25","doi-asserted-by":"publisher","first-page":"9802","DOI":"10.1038\/s41467-024-54077-5","volume":"15","author":"O Kim-McManus","year":"2024","unstructured":"Kim-McManus, O., J. G. Gleeson, and L. Mignon et al. 2024. A framework for N-of-1 trials of individualized gene-targeted therapies for genetic diseases. Nature Communications 15(1):9802. https:\/\/doi.org\/10.1038\/s41467-024-54077-5","journal-title":"Nature Communications"},{"issue":"8","key":"10381_CR26","doi-asserted-by":"publisher","first-page":"602","DOI":"10.2471\/BLT.12.113985","volume":"91","author":"J Kutzin","year":"2013","unstructured":"Kutzin, J. 2013. Health financing for universal coverage and health system performance: concepts and implications for policy. Bulletin Of The World Health Organization 91(8):602\u2013611. https:\/\/doi.org\/10.2471\/BLT.12.113985","journal-title":"Bulletin Of The World Health Organization"},{"issue":"2","key":"10381_CR27","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1093\/heapol\/czaf086","volume":"41","author":"A Lal","year":"2026","unstructured":"Lal, A. 2026. Towards a coherent global health architecture: perspectives on integrating global health security and universal health coverage through diplomacy and governance reforms. Health Policy Plan 41(2):162\u2013175. https:\/\/doi.org\/10.1093\/heapol\/czaf086","journal-title":"Health Policy Plan"},{"key":"10381_CR28","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhealeco.2017.05.004","volume":"56","author":"TJ Layton","year":"2017","unstructured":"Layton, T.J., R.P. Ellis, T.G. McGuire, and R. van Kleef. 2017. Measuring efficiency of health plan payment systems in managed competition health insurance markets. Journal of Health Economics 56: 237\u2013255. https:\/\/doi.org\/10.1016\/j.jhealeco.2017.05.004.","journal-title":"Journal of Health Economics"},{"issue":"Suppl 5","key":"10381_CR29","first-page":"S65","volume":"97","author":"P Leelahavarong","year":"2014","unstructured":"Leelahavarong, P. 2014. Budget impact analysis. Journal Of The Medical Association Of Thailand 97(Suppl 5):S65\u201371.","journal-title":"Journal Of The Medical Association Of Thailand"},{"issue":"9","key":"10381_CR30","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1046\/j.1525-1497.1997.07107.x","volume":"12","author":"JS Mandelblatt","year":"1997","unstructured":"Mandelblatt, J. S., D. G. Fryback, M. C. Weinstein, L. B. Russell, and M. R. Gold. 1997. Medicine. Assessing the Effectiveness of Health Interventions for Cost-Effectiveness Analysis. Journal Of General Internal Medicine 12(9):551\u2013558. https:\/\/doi.org\/10.1046\/j.1525-1497.1997.07107.x","journal-title":"Journal Of General Internal Medicine"},{"issue":"3","key":"10381_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16030332","volume":"16","author":"L Marques","year":"2024","unstructured":"Marques, L., B. Costa, M. Pereira, et al. 2024. Advancing precision medicine: A review of innovative in silico approaches for drug development, clinical pharmacology and personalized healthcare. Pharmaceutics 16 (3): 332. https:\/\/doi.org\/10.3390\/pharmaceutics16030332.","journal-title":"Pharmaceutics"},{"issue":"10","key":"10381_CR32","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.18502\/ijph.v51i10.10975","volume":"51","author":"AM Mosadeghrad","year":"2022","unstructured":"Mosadeghrad, A. M., E. Jaafaripooyan, and M. Zamandi. 2022. Economic Evaluation of Health Interventions: A Critical Review. Iran J Public Health 51(10):2159\u20132170. https:\/\/doi.org\/10.18502\/ijph.v51i10.10975","journal-title":"Iran J Public Health"},{"issue":"1","key":"10381_CR33","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/jpm14010053","volume":"14","author":"G Muharremi","year":"2023","unstructured":"Muharremi, G., R. Me\u00e7ani, and T. Muka. 2023. The Buzz Surrounding Precision Medicine: The Imperative of Incorporating It into Evidence-Based Medical Practice. J Pers Med 14(1):53. https:\/\/doi.org\/10.3390\/jpm14010053","journal-title":"J Pers Med"},{"issue":"7197","key":"10381_CR34","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1136\/bmj.318.7197.1551","volume":"318","author":"S Palmer","year":"1999","unstructured":"Palmer, S., J. Raftery, and Opportunity cost. 1999. Bmj 318(7197):1551\u20131552. https:\/\/doi.org\/10.1136\/bmj.318.7197.1551","journal-title":"Bmj"},{"issue":"12","key":"10381_CR35","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1177\/0960327115601765","volume":"34","author":"C Parsons","year":"2015","unstructured":"Parsons, C. 2015. Insuring the unknown. Human And Experimental Toxicology 34(12):1238\u20131244. https:\/\/doi.org\/10.1177\/0960327115601765","journal-title":"Human And Experimental Toxicology"},{"key":"10381_CR36","unstructured":"Peter, C., and P. C. S. Smith. 2004. Risk Pooling in Health Care Financing: The Implications for Health System Performance. Vol 31595. Accessed March 25, 2026. https:\/\/www.researchgate.net\/publication\/228590900_Risk_Pooling_in_Health_Care_Financing_The_Implications_for_Health_System_Performance"},{"issue":"7","key":"10381_CR37","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jval.2024.02.005","volume":"27","author":"CE Phelps","year":"2024","unstructured":"Phelps, C. E. 2024. Values Beyond Health in Budget-Constrained Healthcare Systems. Value in Health 27(7):830\u2013836. https:\/\/doi.org\/10.1016\/j.jval.2024.02.005","journal-title":"Value in Health"},{"issue":"3","key":"10381_CR38","first-page":"624","volume":"96","author":"AER Prince","year":"2017","unstructured":"Prince, A. E. R. 2017. Insurance Risk Classification in an Era of Genomics: Is a Rational Discrimination Policy Rational? Neb Law Rev 96(3):624\u2013687.","journal-title":"Neb Law Rev"},{"issue":"3","key":"10381_CR39","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/jlb\/lsz001","volume":"5","author":"AER Prince","year":"2019","unstructured":"Prince, A. E. R. 2019. Political economy, stakeholder voices, and saliency: lessons from international policies regulating insurer use of genetic information. J Law Biosci 5(3):461\u2013494. https:\/\/doi.org\/10.1093\/jlb\/lsz001","journal-title":"J Law Biosci"},{"issue":"15","key":"10381_CR40","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.109.914820","volume":"123","author":"DM Roden","year":"2011","unstructured":"Roden, D. M., R. A. Wilke, H. K. Kroemer, C. M. Stein, and Pharmacogenomics. 2011. The genetics of variable drug responses. Circulation 123(15):1661\u20131670. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.914820","journal-title":"Circulation"},{"issue":"1","key":"10381_CR41","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10198-010-0279-6","volume":"13","author":"AF Roos","year":"2012","unstructured":"Roos, A.F., and F.T. Schut. 2012. Spillover effects of supplementary on basic health insurance: Evidence from the Netherlands. European Journal of Health Economics 13 (1): 51\u201362. https:\/\/doi.org\/10.1007\/s10198-010-0279-6.","journal-title":"European Journal of Health Economics"},{"issue":"1","key":"10381_CR42","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/qjmed\/hcl130","volume":"100","author":"RUGER JP","year":"2007","unstructured":"RUGER JP. 2007. The moral foundations of health insurance. Qjm 100(1):53\u201357. https:\/\/doi.org\/10.1093\/qjmed\/hcl130","journal-title":"Qjm"},{"issue":"1","key":"10381_CR43","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1017\/cts.2023.583","volume":"7","author":"JP Samuel","year":"2023","unstructured":"Samuel, J. P., S. H. Wootton, and J. E. Tyson. 2023. N-of-1 trials: The epitome of personalized medicine? J Clin Transl Sci 7(1):e161. https:\/\/doi.org\/10.1017\/cts.2023.583","journal-title":"J Clin Transl Sci"},{"issue":"4","key":"10381_CR44","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/rmir.70027","volume":"28","author":"NA Scordis","year":"2025","unstructured":"Scordis, N. A., and M. Pompella. 2025. Resilience, risk, and reinvention: The challenges of insurance markets amid technological, behavioral, and systemic shocks. Risk Management and Insurance Review 28(4):695\u2013717. https:\/\/doi.org\/10.1111\/rmir.70027","journal-title":"Risk Management and Insurance Review"},{"issue":"1","key":"10381_CR45","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/jalm\/jfad091","volume":"9","author":"MY Tjota","year":"2024","unstructured":"Tjota, M.Y., J.P. Segal, and P. Wang. 2024. Clinical utility and benefits of comprehensive genomic profiling in cancer. Journal of Applied Laboratory Medicine 9 (1): 76\u201391. https:\/\/doi.org\/10.1093\/jalm\/jfad091.","journal-title":"Journal of Applied Laboratory Medicine"},{"key":"10381_CR46","doi-asserted-by":"publisher","unstructured":"Tulchinsky, T. H. Bismarck and the Long Road to Universal Health Coverage. Case Studies in Public Health. Published online 2018:131\u2013179. https:\/\/doi.org\/10.1016\/B978-0-12-804571-8.00031-7","DOI":"10.1016\/B978-0-12-804571-8.00031-7"},{"issue":"9","key":"10381_CR47","first-page":"545","volume":"38","author":"CL Ventola","year":"2013","unstructured":"Ventola, C. L. 2013. Role of Pharmacogenomic Biomarkers In Predicting and Improving Drug Response. P T 38(9):545\u2013560.","journal-title":"P T"},{"issue":"2","key":"10381_CR48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1002\/cpt.1835","volume":"108","author":"RA Vreman","year":"2020","unstructured":"Vreman, R.A., H. Naci, W.G. Goettsch, et al. 2020. Decision making under uncertainty: Comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Clinical Pharmacology and Therapeutics 108 (2): 350\u2013357. https:\/\/doi.org\/10.1002\/cpt.1835.","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"15","key":"10381_CR49","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15153837","volume":"15","author":"RC Wang","year":"2023","unstructured":"Wang, R.C., and Z. Wang. 2023. Precision medicine: Disease subtyping and tailored treatment. Cancers 15 (15): 3837. https:\/\/doi.org\/10.3390\/cancers15153837.","journal-title":"Cancers"},{"issue":"6","key":"10381_CR50","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40273-023-01265-8","volume":"41","author":"B Wouterse","year":"2023","unstructured":"Wouterse, B., P. van Baal, M. Versteegh, and W. Brouwer. 2023. The Value of Health in a Cost-Effectiveness Analysis: Theory Versus Practice. Pharmacoeconomics 41(6):607\u2013617. https:\/\/doi.org\/10.1007\/s40273-023-01265-8","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"10381_CR51","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1177\/0272989X211053792","volume":"42","author":"SJ Wright","year":"2022","unstructured":"Wright, S.J., W.G. Newman, and K. Payne. 2022. Quantifying the impact of capacity constraints in economic evaluations: An application in precision medicine. Medical Decision Making 42 (4): 538\u2013553. https:\/\/doi.org\/10.1177\/0272989X211053792.","journal-title":"Medical Decision Making"},{"key":"10381_CR52","first-page":"26","volume-title":"Risk Pooling and Redistribution in Health Care: An Empirical Analysis of Attitudes toward Solidarity","author":"Chris James Ws","year":"2010","unstructured":"Ws, Chris James. 2010. Risk Pooling and Redistribution in Health Care: An Empirical Analysis of Attitudes toward Solidarity, 26. WHO."},{"issue":"4","key":"10381_CR53","doi-asserted-by":"publisher","first-page":"372","DOI":"10.25251\/skin.5.4.6","volume":"5","author":"J Wu","year":"2021","unstructured":"Wu, J., P. Montgomery, and B. Long et al. 2021. An Economic Evaluation of The Budget Impact of Precision Medicine Testing for The Treatment of Psoriasis. J of Skin 5(4):372\u2013387. https:\/\/doi.org\/10.25251\/skin.5.4.6","journal-title":"J of Skin"},{"issue":"1","key":"10381_CR54","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41746-025-02259-w","volume":"9","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y., Z. Lin, and Y. Teerawattananon et al. 2025. The value for money of artificial intelligence-empowered precision medicine: a systematic review and regression analysis. npj Digit Med 9(1):78. https:\/\/doi.org\/10.1038\/s41746-025-02259-w","journal-title":"npj Digit Med"}],"container-title":["Medicine, Health Care and Philosophy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-026-10381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11019-026-10381-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11019-026-10381-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T08:22:33Z","timestamp":1791534153000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11019-026-10381-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,11]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["10381"],"URL":"https:\/\/doi.org\/10.1007\/s11019-026-10381-z","relation":{},"ISSN":["1386-7423","1572-8633"],"issn-type":[{"value":"1386-7423","type":"print"},{"value":"1572-8633","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,11]]},"assertion":[{"value":"28 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"the authors declares no competing interests.","order":1,"name":"Ethics","label":"Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}